E
44.75
-0.39 (-0.86%)
| Penutupan Terdahulu | 45.14 |
| Buka | 45.43 |
| Jumlah Dagangan | 2,253,359 |
| Purata Dagangan (3B) | 2,612,783 |
| Modal Pasaran | 11,998,019,584 |
| Harga / Pendapatan (P/E TTM) | 16.10 |
| Harga / Pendapatan (P/E Ke hadapan) | 13.76 |
| Harga / Jualan (P/S) | 5.15 |
| Harga / Buku (P/B) | 5.09 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2026 |
| Margin Keuntungan | 27.99% |
| Margin Operasi (TTM) | 33.64% |
| EPS Cair (TTM) | 2.19 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 30.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 327.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.78% |
| Nisbah Semasa (MRQ) | 3.50 |
| Aliran Tunai Operasi (OCF TTM) | 842.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 559.13 M |
| Pulangan Atas Aset (ROA TTM) | 18.05% |
| Pulangan Atas Ekuiti (ROE TTM) | 30.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Exelixis, Inc. | Menurun | Menaik |
AISkor Stockmoo
-0.8
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.80 |
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.20% |
| % Dimiliki oleh Institusi | 93.99% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 54.00 (HC Wainwright & Co., 20.67%) | Beli |
| Median | 44.00 (-1.68%) | |
| Rendah | 35.00 (Wells Fargo, -21.79%) | Pegang |
| Purata | 44.83 (0.18%) | |
| Jumlah | 1 Beli, 5 Pegang | |
| Harga Purata @ Panggilan | 42.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 02 Mar 2026 | 43.00 (-3.91%) | Pegang | 41.03 |
| 11 Feb 2026 | 46.00 (2.79%) | Pegang | 42.94 | |
| HC Wainwright & Co. | 12 Feb 2026 | 54.00 (20.67%) | Beli | 42.70 |
| 03 Feb 2026 | 52.00 (16.20%) | Beli | 42.59 | |
| Stifel | 11 Feb 2026 | 44.00 (-1.68%) | Pegang | 42.94 |
| Wells Fargo | 11 Feb 2026 | 35.00 (-21.79%) | Pegang | 42.94 |
| Barclays | 04 Feb 2026 | 44.00 (-1.68%) | Pegang | 42.65 |
| Morgan Stanley | 02 Feb 2026 | 49.00 (9.50%) | Pegang | 42.81 |
| 08 Jan 2026 | 48.00 (7.26%) | Pegang | 44.15 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |